Because we had found that flotillin-1 levels in the serum and CSF of patients with AD are lower than those in healthy controls and show an inverse correlation with cerebral amyloid deposition, supporting its potential as a biomarker for AD [10,11]. Here, FLOT1 is linked to Alzheimer disease.